Connect with us

Subscribe

vaccine
Photo by Crawford Jolly on Unsplash

biotech

COVID-19 vaccine 90% effective

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.” The words of Dr Albert Bourla, Chairman and CEO of Pfizer, the company, along with BioNTech, behind the vaccine candidate that today was revealed to be 90% effective in preventing COVID-19.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Dr Bourla said. “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

Submissions for Emergency Use Authorization (EUA) are expected to be made to the U.S. Food and Drug Administration (FDA) in the third week of November. And it expected that up to 50 million vaccine doses will be available this year and 1.3 billion doses in 2021.

Newsletter Signup

Written By

Susan is the co-founder of Innovators Magazine and a consultant for OnePoint5Media. Susan is also a member of the UNFCCC-led Resilience Frontiers Nexus group and the Chair of the APOPO Foundation UK board.

How to switch on your memory when you need it

creativity

Changemakers are flocking to the new world of EU innovation

Editor's Picks

Private funds to finance new era of European dynamism 

Editor's Picks

New research on the way diet impacts how you age

Editor's Picks

Connect
Newsletter Signup